Format

Send to

Choose Destination
Neuroradiology. 2008 Oct;50(10):855-61. doi: 10.1007/s00234-008-0413-7. Epub 2008 Jun 4.

No advantage of time-of-flight magnetic resonance angiography at 3 Tesla compared to 1.5 Tesla in the follow-up after endovascular treatment of cerebral aneurysms.

Author information

1
Department of Neuroradiology, University of Göttingen, Robert-Koch-Str. 40, 37075, Goettingen, Germany. jbuhk@gwdg.de

Abstract

INTRODUCTION:

Long-term follow-up after coil embolization of intracranial aneurysms is mandatory to monitor coil compacting and aneurysm recurrence. Most centers perform one digital subtraction angiography (DSA) on follow-up continuing with time-of-flight magnetic resonance angiography (TOF-MRA). This study explores the diagnostic value of TOF-MRA at 1.5 T versus 3 T compared to DSA.

MATERIALS AND METHODS:

In 18 patients with 20 aneurysms treated with coil embolization, TOF-MRA at 1.5 and 3 T were performed the day before follow-up DSA, the latter serving as reference. Optimized diagnostic protocols were applied (1.5 T: 0.78 x 0.55 x 0.8 mm, voxel size; acquisition time (TA), 6.37 min; 3 T: 0.56 x 0.45 x 0.65 mm, voxel size; TA, 3.12 min). Three independent neuroradiologists experienced in neuroendovascular therapy rated the occlusion rate ("complete occlusion" vs. "residual neck" vs. "residual aneurysm") and compared the two methods subjectively. Weighted kappa statistics were calculated to assess the level of interobserver agreement.

RESULTS:

Compared to DSA, TOF-MRA was more sensitive in detecting neck remnants, with a slight advantage at 3 T. Regarding artifact load, there are advantages at 1.5 T. Ratings of the occlusion rate correlated highly between all observers (r > 0.85, p < 0.001, respectively). Interobserver agreement was high in all cases (small ka, Cyrillic (w) approximately 0.8, respectively).

CONCLUSION:

TOF-MRA is a reliable tool for follow-up imaging of cerebral aneurysms after endovascular treatment. Our study shows no advantage of TOF-MRA at 3 T over 1.5 T, when comparable measurement protocols are applied. TOF-MRA at 1.5 T therefore provides appropriate information regarding a therapeutic decision.

PMID:
18523761
DOI:
10.1007/s00234-008-0413-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center